Articles by Pablo Tebas

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults

Tebas, Pablo; Spitsin, Sergei; Barrett, Jeffrey S.; More

AIDS. 29(8):931-939, May 15th, 2015.

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1...

Palella, Frank J. Jr; Fisher, Martin; Tebas, Pablo; More

AIDS. 28(3):335-344, January 28th, 2014.

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals

Tebas, Pablo; Frank, Ian; Lewis, Mark; More

AIDS. 24(14):2187-2192, September 10th, 2010.

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV

McComsey, Grace A; Kendall, Michelle A; Tebas, Pablo; More

AIDS. 21(18):2473-2482, November 30th, 2007.

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen

Fischl, Margaret A; Collier, Ann C; Mukherjee, A Lisa; More

AIDS. 21(3):325-333, January 30th, 2007.

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

Dubé, Michael P; Parker, Robert A; Tebas, Pablo; More

AIDS. 19(16):1807-1818, November 4th, 2005.